Pin105 - The Public Health Impact of Tick-Borne Encephalitis Vaccination on the Slovenian Adult Population

Abstract

OBJECTIVES: In Europe, meningococcal serogroup B is the most common cause of invasive meningococcal disease. The disease incidence is the highest among infants, young children and adolescents, while adolescents are considered the key transmitters of meningococci in the population. The disease is rare, but deadly and can cause permanent sequelae. The two new vaccines (4CMenB and rLP2086) were licensed in 2013 and 2017, respectively. Although the cost-effectiveness of vaccination with the vaccine 4CMenB has been assessed, only Ireland, Italy and England introduced this vaccine in the publicly funded national immunization programme (NIP), while Austria and the Czech Republic recommended it but without funding. The aim of the review is to summarise lessons learned from the cost-effectiveness studies and according to that contribute to decision-making for introducing the vaccine in the NIP in the remaining European countries. METHODS: The databases of PubMed and NHS EED were searched systematically to identify contributions (up to April 15, 2018) on the cost-effectiveness of vaccination with the new vaccines versus no vaccination. Keywords like meningococcal, serogroup B, 4CMenB, rLP2086 and cost-effectiveness were used. The quality of these studies was assessed according to the CHEERS checklist, they were only in English, performed for European countries and included different age groups. The main characteristics of the included studies were extracted. RESULTS: A total of nine cost-effectiveness studies were analysed. According to these analyses, vaccination is likely not costeffective due to low incidence of the disease. CONCLUSIONS: Infant vaccination is a relevant strategy to public health in the short run, while adolescent vaccination may be a more effective strategy in the long run, if herd effects are taken into account.OBJECTIVES: Two MenB vaccines are licensed in the US since 2015: MenB-FHbp and MenB-4C, with a category B recommendation for vaccination at ages 16-23. Both vaccines were approved based on immune responses after series completion, but different dosing schedules and recommendations apply: MenB-4C, 2 doses at least 1 month apart; MenB-FHbp: initially 3 doses (at 0, 1-2, and 6 months), now 2 doses 6 months apart. This study evaluated completion and compliance for MenB-4C or MenB-FHbp vaccination (considering both 2-or 3-dose schedules) in individuals aged 16-23. METHODS: This was a retrospective analysis based on claims data from MarketScan Commercial Claims and Encounters through 2/28/2018. The study population included individuals who initiated MenB-4C or MenB-FHbp between 7/1/2015 and 11/30/2016, with continuous health plan enrollment for 6 months prior and 15 months after series initiation. Series completion was defined as individual receipt of the recommended number of doses within the follow-up period, while compliance was based on adherence to recommended dosing schedule for each vaccine. Current recommendations for MenB-FHbp were applied retroactively. RESULTS: 36,118 individuals met the in...